By Brad Sorensen, CFA
NASDAQ: COSM
READ THE FULL COSM RESEARCH REPORT
Cosmos Health (NASDAQ: COSM) has spent the past several years building what management describes as a vertically integrated healthcare platform spanning pharmaceutical manufacturing, distribution, proprietary brands, nutraceuticals, R&D, and telehealth. Two announcements released on September 28 and September 29 provide compelling evidence that those investments are beginning to translate into meaningful operating growth. We believe the developments at Cana Laboratories and CosmoFarm are especially important because they involve existing businesses generating commercial revenue today rather than relying primarily on future product development.
The September 29 announcement highlighted the continued expansion of CosmoFarm, Cosmos Health's pharmaceutical distribution subsidiary in Greece. CosmoFarm generated more than $15 million of revenue during the second quarter of 2026, its highest quarterly level to date, implying an annualized revenue run rate above $60 million. For perspective, CosmoFarm generated approximately $14 million of revenue in fiscal 2017, before being acquired by Cosmos Health. On that basis, the business is now operating at roughly 4.3 times its pre-acquisition revenue level.
Even more important than the headline revenue number is how that growth has been achieved. CosmoFarm's overall pharmacy network has expanded from more than 1,130 pharmacies at acquisition to more than 1,500 today, while the number of pharmacies it serves on a daily basis has increased from approximately 100 in 2017 to roughly 360. The company added nearly 100 pharmacy customers organically during 2025 and more than 80 additional pharmacies during the second quarter of 2026 alone.
That progression demonstrates to us that Cosmos is not simply benefiting from pharmaceutical price inflation or currency movements. The underlying distribution network itself has become considerably larger.
Management is now preparing CosmoFarm for another step upward. Cosmos has invested several million euros in robotics and automation and is introducing additional artificial intelligence into procurement, inventory management and order fulfillment. The company believes facility expansion and additional robotic capacity can accommodate at least another $40 million of annual revenue, potentially giving CosmoFarm infrastructure capable of supporting more than $100 million in annualized revenue.
Investors should distinguish capacity from actual revenue: $100 million is not current revenue or contracted sales. Cosmos must still attract the customers and volumes required to utilize that capacity. Nevertheless, building the infrastructure before the volume arrives potentially creates meaningful operating leverage. Once warehouses, routing systems, personnel and robotics are in place, additional pharmacy volume can be handled at a lower incremental cost than the original volume.
Cosmos is pursuing both organic growth and acquisitions to fill that capacity. The company disclosed that it has signed a letter of intent involving another pharmacy network generating approximately €10 million, or roughly $11.5 million, in annual gross revenue. The transaction remains subject to a definitive agreement and customary closing conditions. If completed, however, as we believe it will, it would further advance the consolidation strategy the company has been pursuing in Greece's fragmented pharmaceutical distribution industry.
The importance of CosmoFarm extends beyond distribution revenue. Its pharmacy relationships also provide Cosmos with a direct channel through which it can distribute its own higher-margin products, including brands such as Sky Premium Life and C-Scrub. That is where the vertical integration strategy becomes more interesting financially: Cosmos can potentially participate in manufacturing economics, brand economics, and distribution economics instead of capturing only one piece of the value chain.
The September 28 announcement involving Cana Laboratories provides a complementary piece of that strategy.
Cana's contract-manufacturing pipeline has now exceeded 32.7 million units, representing more than $20 million of estimated revenue and more than $18 million of estimated gross profit over the lives of the underlying agreements. Management estimates gross margins on the current contract-manufacturing pipeline at greater than 90%. The agreements have an average duration of approximately four years, with some extending as long as ten years. On an annualized basis, Cosmos estimates the existing pipeline represents approximately $5 million of revenue and approximately $4.5 million of gross profit.
Those economics could be unusually valuable for Cosmos because, under most of Cana's contract-manufacturing agreements, customers provide the raw materials while Cana provides manufacturing capacity, regulatory expertise and quality assurance. That structure helps explain why management believes the business can achieve gross margins dramatically above Cosmos Health's consolidated corporate margin.
The pace of growth is also notable to us and should be to investors. Cana's manufacturing pipeline has increased approximately sixfold since mid-2024 and nearly tripled since the beginning of 2026. It increased another 31% since June and added 7.7 million units during September through two new long-term agreements. The current contracts span 11 therapeutic categories, reducing dependence on any single product area or manufacturing customer.
This progress provides some validation for the approximately $5.5 million Cosmos has invested in modernizing Cana's 54,000-square-foot Athens manufacturing facility. The company has upgraded equipment, IT infrastructure, and quality-management systems and recently installed a new capsule-filling production line. Cana operates under European GMP standards and is certified by the European Medicines Agency, allowing the facility to manufacture pharmaceuticals, supplements, cosmetics, biocides and medical devices for European and international markets.
Importantly, the current manufacturing pipeline still utilizes only part of Cana's available capacity. Cosmos is targeting more than $10 million in recurring annual gross profit from contract manufacturing at full utilization, versus approximately $4.5 million implied by today's pipeline. That target remains forward-looking and depends upon Cosmos continuing to win manufacturing contracts and successfully converting contracted pipelines into actual orders.
Taken together, the two announcements illustrate what may be the most important evolution in the Cosmos Health story: the company increasingly has multiple operating engines that can reinforce one another.
CosmoFarm provides scale and distribution. Cana provides manufacturing and potentially very high-margin contract revenue. Cosmos' proprietary brands can utilize both systems, with Cana producing products and CosmoFarm providing direct access to pharmacies. Growing outside manufacturing contracts help absorb Cana's fixed costs, while growing pharmacy distribution volumes improve utilization of CosmoFarm's infrastructure. In principle, each additional piece of business can therefore improve the economics of assets Cosmos already owns.
To us, the strongest interpretation of the September 28 and September 29 announcements is that Cosmos' strategy is beginning to shift from building infrastructure to monetizing it. CosmoFarm shows that management can acquire an established asset and substantially increase its scale. Cana is beginning to demonstrate the same potential in manufacturing. If Cosmos can continue filling the available capacity in both businesses while expanding its proprietary higher-margin products through the same manufacturing and distribution infrastructure, the company could increasingly benefit from the operating leverage inherent in the vertically integrated model it has spent years assembling.
Compared with the Cosmos of several years ago, today's business has considerably more revenue, a rapidly growing manufacturing backlog, a larger distribution network, stronger physical infrastructure and a cleaner balance sheet. The latest two announcements provide additional evidence that the company's growth strategy is increasingly producing measurable operating results rather than simply future aspirations and we urge investors to take a take a look at COSM and consider the new and improved investment opportunity.
SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you. Please visit our website for additional information on Zacks SCR.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives payments totaling a maximum fee of up to $50,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.